Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00355589
Other study ID # K749-06-3001
Secondary ID B5051001
Status Completed
Phase Phase 3
First received July 20, 2006
Last updated October 8, 2012
Start date July 2006
Est. completion date March 2007

Study information

Verified date October 2012
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if there is greater blood pressure reduction using ramipril or hydrochlorothiazide alone or ramipril and hydrochlorothiazide together.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date March 2007
Est. primary completion date March 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Previously diagnosed, or newly diagnosed essential hypertension. Blood pressure must be within a minimum and maximum range prior to drug treatment.

Exclusion Criteria:

- Inability to discontinue all prior antihypertensive medications

- Heart failure

- History of stroke, myocardial infarction, or chest pain within 3 years, or an abnormal heart rhythm

- Liver or kidney disease

- Certain drugs used to treat other conditions like an enlarged prostate gland, or arthritis

- Allergy or reactions to certain medications used to treat high blood pressure

Other protocol-defined inclusion and exclusion criteria apply.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Ramipril and hydrochlorothiazide


Locations

Country Name City State
United States Executive Health and Research Associates, Inc. Atlanta Georgia
United States MetaClin Research, Inc. Austin Texas
United States Impact Clinical Trials Beverly Hills California
United States Lovelace Scientific Resources, Inc. Beverly Hills California
United States Cahaba Research Inc. Birmingham Alabama
United States Twin Cities Clinical Research Brooklyn Center Minnesota
United States Associated Pharmaceutical Research Center, Inc. Buena Park California
United States Punzi Medical Center Carrollton Texas
United States Medical Research South Charleston South Carolina
United States Cedar Crosse Research Center Chicago Illinois
United States James R. Herron, MD, Ltd. Chicago Illinois
United States Sterling Research Group, Inc. Cincinnati Ohio
United States Clinical Research of West Florida, Inc. Clearwater Florida
United States SC Clinical Research Center, LLC Columbia South Carolina
United States Clinical Research of South Florida Coral Gables Florida
United States Research Across America Dallas Texas
United States University Clinical Research Deland, Inc. Deland Florida
United States University of Connecticut Health Center Farmington Connecticut
United States Cumberland Research Assocites, LLC Fayetteville North Carolina
United States Pulmonary Associates Glendale Arizona
United States Marin Endocrine Care and Research Greenbrae California
United States Radiant Research - Greer Greer South Carolina
United States Clinical Investigation Specialists, Inc. Gurnee Illinois
United States Unifour Medical Research Associates Hickory North Carolina
United States South Florida Clinical Research Center Hollywood Florida
United States Clinical Research Associates Huntsville Alabama
United States Midwest Institute for Clinical Research Indianapolis Indiana
United States Radiant Research - Tacoma Lakewood Washington
United States Innovative Research of West Florida Largo Florida
United States Advanced Biomedical Research of America Las Vegas Nevada
United States Michigan Institute of Medicine Livonia Michigan
United States Memorial Research Medical Clinic Long Beach California
United States National Research Institute Los Angeles California
United States The Intermed Group; Samaritan Medical Tower Los Angeles California
United States Smith Clinical Research Marion Ohio
United States Medford Medical Clinic Research Dept. Medford Oregon
United States International Research Associates, LLC Miami Florida
United States Lifespan Research Foundation Miami Florida
United States Radiant Research - Mogadore Mogadore Ohio
United States Sun Coast Clinical Research New Port Richey Florida
United States Clinical Research Associates of Tidewater Norfolk Virginia
United States Lion Research Norman Oklahoma
United States Renstar Medical Research Ocala Florida
United States Suncoast Clinical Research, Inc. Palm Harbor Florida
United States University Clinical Research, Inc. Pembroke Pines Florida
United States Philadelphia Health Associates Philadelphia Pennsylvania
United States Triangle Medical Research Associates Raleigh North Carolina
United States Clinical Trials Research Roseville California
United States Radiant Research - San Antonio San Antonio Texas
United States WellMed Medical Management San Antonio Texas
United States Lovelace Scientific Resources Sarasota Florida
United States The Lipid Center Statesville North Carolina
United States Bayview Research Group Studio City California
United States Viking Clinical Research Temecula California
United States Medical Research Associates Traverse City Michigan
United States The Chase Wellness Center, Inc Virginia Beach Virginia
United States Partners in Primary Care Voorhees New Jersey
United States Metabolic Research Institute, Inc. West Palm Beach Florida
United States Lyndhurst Gynecologic Associates, PA Winston-Salem North Carolina
United States Piedmont Medical Research Associates Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare the effects on sitting diastolic blood pressure of two antihypertensive drugs in combination against each antihypertensive alone after an eight week treatment period.
Secondary Compare the effect on sitting diastolic blood pressure of two antihypertensive drugs in combination taken once daily against one antihypertensive drug taken twice daily.
Secondary Compare the effect on sitting diastolic blood pressure of a dose of an antihypertensive drug taken once daily against half of the same dose taken twice daily.
Secondary Compare the effect on the sitting and standing blood pressure among all treatment groups.
Secondary Compare the safety of each medication regimen stated above.
Secondary Compare the effect on mean 24-hour diastolic blood pressure (ABPM) of the medication regimens stated above.
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A